Data from early trials have shown.
The phase one and phase two results suggest that one of the groups most at risk of death or serious illness from COVID-19 may be able to build immunity, according to data published in The Lancet medical journal.
The COVID-19 vaccine developed by Oxford University produces a strong immune response in older adults
